DRR168566
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.270
- MYC_TARGETS_V2+0.250
- PROTEIN_SECRETION+0.230
- UV_RESPONSE_DN+0.230
- ADIPOGENESIS+0.190
- CHOLESTEROL_HOMEOSTASIS+0.190
- WNT_BETA_CATENIN_SIGNALING+0.190
- DNA_REPAIR+0.160
- TGF_BETA_SIGNALING+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.450
- INFLAMMATORY_RESPONSE-0.350
- ALLOGRAFT_REJECTION-0.340
- IL6_JAK_STAT3_SIGNALING-0.300
- COMPLEMENT-0.290
- TNFA_SIGNALING_VIA_NFKB-0.270
- APOPTOSIS-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.230
- KRAS_SIGNALING_UP-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0I8-01A-11R-A034-07 | — | B | 0.802 |
| 2 | TCGA-C8-A3M8-01A-11R-A213-07 | — | B | 0.791 |
| 3 | MNG268 | — | — | 0.781 |
| 4 | MNG1102 | — | — | 0.762 |
| 5 | 131546 | EPN | EPN Tumor | 0.749 |
| 6 | SRR11296875 | — | — | 0.748 |
| 7 | TCGA-86-8279-01A-11R-2287-07 | — | cohortA1 | 0.746 |
| 8 | SRR2932825 | — | — | 0.738 |
| 9 | 9f9dec84-0c2c-4f85-8024-b8fb1de1eb81 | — | — | 0.732 |
| 10 | SRR13311175 | — | — | 0.728 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |